Kalaris to Participate at Stifel Ophthalmology Forum
Rhea-AI Summary
Kalaris Therapeutics (NASDAQ: KLRS), a clinical-stage biopharmaceutical company focused on retinal disease treatments, announced its participation in the Stifel 2025 Virtual Ophthalmology Forum. The company's management, including CEO Andrew Oxtoby and CMO Matthew Feinsod, will engage in a Fireside Chat on Tuesday, May 27th, 2025, at 8:00 AM ET. A replay of the event will be available on the company's Investor Relations webpage.
Positive
- None.
Negative
- None.
News Market Reaction – KLRS
On the day this news was published, KLRS declined 1.41%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum.
Details:
- Type: Fireside Chat
- Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
- Date: Tuesday, May 27th, 2025
- Time: 08:00 am ET
- Location: Webcast
Following the event, a replay will be hosted on Kalaris Therapeutics’ Investor Relations webpage.
About Kalaris
Kalaris is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. The company is focused on development of TH103, a novel, differentiated anti-VEGF investigational therapy. Developed by Dr. Napoleone Ferrara, TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is currently being evaluated in an ongoing, Phase 1 clinical trial for the treatment of neovascular Age-related Macular Degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as Diabetic Macular Edema (DME), and Retinal Vein Occlusion (RVO).
Kalaris Therapeutics Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
+1 212 915 2577
FAQ
When is Kalaris Therapeutics (KLRS) presenting at the Stifel Ophthalmology Forum 2025?
Who will represent Kalaris Therapeutics at the Stifel 2025 Ophthalmology Forum?
What type of company is Kalaris Therapeutics (KLRS)?
How can investors access the Kalaris Therapeutics Stifel presentation replay?
